GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

The PREDICT-RT study stratifies enrolled patients with high-risk cancer by Decipher Risk Score. Decipher testing was conducted by Veracyte, Inc. (VCYT), a global diagnostics company that provides high ...

Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy. Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase ...

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ...

Findings are among nine Decipher-focused abstracts being presented at annual conference “We look forward to the presentation of important new data examining the role of adverse molecular features in ...

Among the 832 patients with metastatic prostate cancer, those with high Decipher Prostate scores had a 36% reduction in the risk of death after treatment with docetaxel, while those with lower ...

PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate ...

The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk prostate cancer showed a 25-year overall survival rate of 94% and a ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...